Neither ORP100S nor GM‐CSF interfered with the anti‐tumor activity of 5‐FU (Figure 5E,F), and both ORP100S and GM‐CSF showed comparable efficacy in reducing neutropenia (Figure 5G). The gene discussed is CSF2; the disease is Decreased total neutrophil count.